Go-to-Market · Day-30 Product Owner POV · v1.0 (2026-05-21)

Expansion, not acquisition.

ZoomRx already serves 19 of the top 20 global pharma - procurement, MSAs and buyer relationships are solved. The GTM job isn't acquisition. It's expansion inside the wallet, fast enough to compound before AI-natives arrive.

18 / 20
Top-20 pharma already served: Always-on
Wedge use case: 25-35%
Bolt-on price: Depth
Year-1 risk to watch

01 · The reframe

One question swap. Whole plan changes.

The stated problem

BD doesn't yet know how to sell this product.

What's underneath

BD doesn't know how to sell AI qual into accounts that already buy our trackers - and AI-native entrants will arrive in 12-18 months as the second AI qual vendor in those same accounts if we wait.

What this changes

The GTM question is not acquisition. It is expansion inside existing wallet, sequenced to protect key revenue relationships and compound proof before AI-natives close the door.

02 · 90 days in five windows

What we do. What we explicitly don't.

WindowTitleWhat we doWhat we don't do (yet)

Days 1-15Internal mappingPareto-cut the account book. Overlay BD relationship bond. Populate the 4-quadrant matrix.Don't pitch externally yet. Don't touch whales.

Days 15-30Sell to BD firstPM-pitches-BD · co-build demo · run one real research project end-to-end · lock the wedge use case + pricing range.Don't ship a deck without a live working demo.

Days 30-45Q4 validation pitches5-7 strong-bond long-tail pitches. Goal: 1-2 paid pilots signed at half-bolt-on rate.Don't approach whales. Don't lead with price.

Days 45-60Q6 feedback + whale warm introsPitch 2-3 tough clients for feedback. Begin 3-5 whale warm intros. Lighthouse case study v1.Don't pitch whales yet - just frame and listen.

Days 60-90Anchor pricing + certify + scaleFirst whale anchor-pitch (PM-led). 3-5 paid pilots across Q4/Q5. Certify every BD. Friday Deal Desk live.Don't soften anchor pricing because the whale is large.

Sequencing rationale: validate with strong-bond long-tail accounts → harden the playbook against tough-client feedback → approach whales armed with proof and anchor pricing. Each layer pays for the next.

03 · The wedge use case

Always-on HCP listening. Between tracker waves.

The bet

Trackers capture quarterly snapshots. The 12-week gap between snapshots is where real brand decisions are made - and that gap has no traditional qual answer. We sell Sagan as a 25-35% bolt-on to existing tracker contracts. New line item. No procurement re-cycle. No cannibalization.

Why it wins

Expands wallet, doesn't replace it

Tracker clients already spend $200-500K/yr. Always-on listening creates a new line item, not a redirected one.

Why it wins

Rides existing infrastructure

MSAs signed. Procurement onboarded. Buyer relationships known. BD does not need to introduce a new vendor.

Why it wins

No traditional alternative

Continuous, async HCP listening at this cost is impossible with IDIs / focus groups. The comparison is 'AI qual or nothing.'

Why it wins

Anchors expansion in Year 2

Committed-capacity model (e.g., 100 interviews/yr or 4 listening waves) makes renewal predictable and frames multi-brand framework conversations.

04 · How we sequence accounts

Pareto-cut the book. Pitch the long tail first.

Strong bondMedium bondPoor bond

Whale (top 20%)

Q1Day 60+

Anchor pitch (PM-led)

Whale × Strong

Q2Day 75+

Warm intro only

Whale × Medium

Q3Not Y1

Address relationship

Whale × Poor

Long-tail (80%)

Q4Day 30-45

Validation pitches

Long-tail × Strong

Q5Day 45-60+

Volume conversion

Long-tail × Medium

Q6Day 45-60

Feedback harvest

Long-tail × Poor

First actionSequencedAvoid Y1

Whale accounts (top 20% by revenue) are held until Day 60+. The downside of a botched pitch at a top-3 pharma is felt across the entire account relationship. We approach them last, armed with two case studies and anchor pricing. Full mechanics in Strategy.

05 · Headline risks

Five things that break the plan.

TierRiskEarly signal

HIGHPenetration depth fails inside converted accounts<40% of client's research engagement flows through Sagan by EOY → niche-vendor trap

HIGHAnnual-plan inclusion miss (Sept-Nov window)<50% of pilot clients name Sagan in next year's research plan → renewal motion broken

HIGHAI-native entrant lands as second vendor in our account'We're already piloting [Outset / Listen Labs]' in 3+ discoveries within 90 days

MEDBD perceives Sagan as cannibalizing their IDI bookBD won't quote Sagan unprompted in client meetings → comp + positioning fix needed

MEDPilot quality SLA misses on first 2 dealsProbe rate <0.6 or depth <3.5 on the lighthouse pilot → product gate, halt sales

06 · Drill in

Three sub-views. Each opinionated.

07 · Market & Buyer

The market is inside our existing book

External TAM context · pharma logo gap on AI-natives · wedge use case selection (3 candidates, 1 winner) · buyer org chart · 1L EGFR+ NSCLC reference case.

Open →

08 · Strategy